XORTX Announces New Clinical Advisory Board Member.
XORTX Therapeutics, a biopharmaceutical company focused on treating autosomal dominant polycystic kidney disease (ADPKD), has announced the addition of Dr. Ronald Perrone to its Clinical Advisory Board. Dr. Perrone, a professor of medicine at Tufts University School of Medicine, brings substantial medical and professional experience to the board. The company anticipates valuable contributions from Dr. Perrone as they continue to develop innovative therapies for ADPKD.
March 27, 2024
5 Articles